Home   |   Contact Us
Lixivaptan

We are developing this drug for treatment of hyponatremia and water retention in heart failure patients.

Click here to learn more
February 14, 2008 BIOGEN IDEC AND CARDIOKINE INITIATE PHASE III CLINICAL TRIAL FOR LIXIVAPTAN IN CONGESTIVE HEART FAILURE PATIENTS WITH HYPONATREMIA
   
January 22, 2008 DR. MANUEL WORCEL APPOINTED CEO AND PRESIDENT OF CARDIOKINE
   
September 17, 2007 CEO AND PRESIDENT DAVID BRAND TO LEAVE CARDIOKINE
   
July 2, 2007 BIOGEN IDEC AND CARDIOKINE PARTNER TO DEVELOP LIXIVAPTAN, A NOVEL VASOPRESSIN ANTAGONIST
   
May 1, 2006 CardioKine, Inc. Closes $50 Million Series B Financing
   
July 27, 2004 CardioKine, Inc. Names Industry Veteran David Brand as CEO
   
April 13, 2004 CardioKine Completes $37 Million Private Equity Financing

 
© Copyright 2005 CardioKine. All Rights Reserved.            Designed by Osiris Group, Inc.